Pioneering gene therapies for rare central nervous system (CNS) diseases Free

Info

Please note that for mobiles we stream the presentation slides and audio of the speaker.

x Mobile version: slides + audio only
-15s 00:00 / 30:20 +15s
Minimise video

Ms Karen Aiach begins by explaining Lysogene's progress in using gene therapy to treat young children with rare CNS diseases, using her experience with her own child. Dr Michel Zerah continues, revealing Lysogene’s work, from direct-to-brain therapy to the optimisation of the surgical procedure.

This lecture was filmed at the Royal Society of Medicine's 14th Medical Innovations Summit on April 22nd 2017

Length: 00:30:20

00:00:01 - Introduction to Lysogene
00:09:52 - Michel Zerah and Gene Therapy
00:16:29 - From Research to Therapy
00:28:48 - Conclusion and Lysogene's Progress
00:00:01
00:02:19
00:04:20
00:08:05
00:09:52
00:11:20
00:13:18
00:14:28
00:15:35
00:16:29
00:17:20
00:22:30
00:24:45
00:28:48
00:30:15
51:06

Professor Sir Mark Walport, Director of the Wellcome Trust.

Archived View
35:53

Mr Ben Challacombe, Consultant Urological Surgeon at Guy's and St Thomas' NHS Foundation Trust.

 

Free Archived View
38:25

Professor Tom Waddell, Professor of Thoracic and Lung Transplant Surgery, University of Toronto.

Archived View
25:30

Professor Adrian Hill, Chairman of the Centre for Clinical Vaccinology and Tropical Medicine at Oxford University. 

Free Archived View
28:05

Dr Alun Morgan and Mrs Gill Davies, ZooBiotic.

Free Archived View
26:45

Dr Paul Sobotka, Ardian, California and Dr Mel Lobo, Barts and the London NHS Trust. 

Free Archived View
29:24

Peter Suma and Peter Ellis, Pharmatrust, Canada and the UK.

Free Archived View
37:46

Dr Frederic Moll, President and CEO Hansen Medical Inc, California.

Free Archived View
16:14

Professor Anan Shetty, Senior tutor in orthopaedics, University of London. 

Free Archived View